Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke (VENTURE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00874601|
Recruitment Status : Unknown
Verified October 2011 by Hallym University Medical Center.
Recruitment status was: Recruiting
First Posted : April 2, 2009
Last Update Posted : October 5, 2011
The manipulation of blood pressure in acute cerebral ischemia has been a matter of debate until now. The investigators are clearly in need of more detailed data on how antihypertensive treatment affects outcome in acute phase of stroke.
This study will assess the effects of modest blood pressure (BP) lowering manipulation in acute period of ischemic stroke on death or dependency at 90-day.
|Condition or disease||Intervention/treatment||Phase|
|Acute Ischemic Stroke||Drug: Diovan® (valsartan)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||578 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke|
|Study Start Date :||October 2008|
|Actual Primary Completion Date :||July 2011|
|Estimated Study Completion Date :||July 2012|
Experimental: valsartan group
The valsartan group will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
Drug: Diovan® (valsartan)
The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded.
No Intervention: control group
Patients on control group will not receive any other antihypertensive medication for first 7 days after stroke onset. However, rescue therapy with antihypertensive agents can be permitted for episodes with severely elevated blood pressures during acute periods.
- Death or dependency measured as functional status with the use of mRDs [ Time Frame: 90 days after the onset ]
- NIHSS [ Time Frame: 7 days and 90 days after stroke onset ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00874601
|Contact: Byung-chul Lee, MD, PhDfirstname.lastname@example.org|
|Contact: Kyung-ho Yu, MD, PhDemail@example.com|
|Korea, Republic of|
|Hallym University Sacred Heart Hospital||Recruiting|
|Anyang, Gyeonggi, Korea, Republic of, 430-070|
|Contact: Byung-chul Lee, MD, PhD +82-31-380-3741 firstname.lastname@example.org|
|Sub-Investigator: Kyung-ho Yu, MD, PhD|
|Principal Investigator:||Byung-chul Lee, MD, PhD||Hallym University Medical Center|